Revolutionizing First-Line Strategies in EGFR-Mutant NSCLC: Combination Therapies
Explore significant updates in the field of EGFR-mutant lung cancer treatment, focusing on the introduction of combination therapy in the first-line setting, including the FLAURA2., MARIPOSA, and RAMOSE trials, offering improved progression-free survival and potential implications for patient care.
CN-NSCLC-ATP-Seg02_FIRSTLINE
Video Player is loading.
Recent Videos
Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL
Personalizing CAR T: Making the Right Call for Each Patient
Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection
CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management
TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL
Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL
Beyond Salvage: When to Move to CAR T in Relapsed DLBCL
DLBCL in Focus: Transforming Outcomes With CAR T Therapy
Closing Reflection: A Journey of Understanding and Resilience
Patient Voices: Shaping the Future of PNH Care
Related Content
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Georgios Evangelou, MD, MSc;Ioannis Vamvakaris, MD, PhD, MSc;Irene Konstantopoulou, PhD;Konstantinos Syrigos, PhD
July 10th 2024Article
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
